• 1
    Osteoporosis Prevention 2000 Diagnosis, and Therapy. NIH Consensus Statement 17:136.
  • 2
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Neritt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, for the Fracture Intervention Trial Research Group 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:15351541.
  • 3
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Conner E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ, for the Fracture Intervention Trial Research Group 1998 Effects of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 208:20772082.
  • 4
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut III CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Residronate Therapy (VERT) Study Group. JAMA 282:13441352.
  • 5
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, and the Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321333.
  • 6
    Riggs BL, Hartmann LC 2003 Selective estrogen-receptor modulators—Mechanisms of action and application to clinical practice. N Engl J Med 348:618629.
  • 7
    Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H III, Gennari C, Christiansen C, Arnaud CD, Delmas PD 2000 Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:34443450.
  • 8
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637645.
  • 9
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen E, Ish-Shalom S, Genaant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:14341441.
  • 10
    Gallagher JC, Goldgar D 1990 Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 113:649655.
  • 11
    Tilyard MW, Spears GF, Thomson J, Dovey S 1992 Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357362.
  • 12
    Shiraki M, Ito H, Orimo H 1992 The ultra long-term treatment of senile osteoporosis with 1α-hydroxyvitamin D3. Bone Miner 20:223234.
  • 13
    Orimo H, Shiraki M, Hayashi T, Nakamura T 1987 Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone Miner 3:4752.
  • 14
    Orimo H, Shiraki M, Hayashi T, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N 1994 Effects of 1 alpha (OH)-vitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370376.
  • 15
    Ringe JD, Cöster A, Meng T, Schacht E, Umback R 1999 Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 65:337340.
  • 16
    Gallagher JC, Fowler SE, Detter JR, Sherman SS 2001 Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 86:36183628.
  • 17
    Riggs BL 2003 Role of the vitamin D-endocrine system in the pathophysiology of postmenopausal osteoporosis. J Cell Biochem 88:209215.
  • 18
    Sairanen S, Kärkkäinen M, Tähtelä R, Laitinen K, Mäkelä P, Lamberg-Allardt C, Välimäki MJ 2000 Bone mass and markers of bone and calcium metabolism in postmenopausal women treated with 1,25-Dihydroxyvitmn D (Calcitriol) for four years. Calcif Tissue Int 67:122127.
  • 19
    Manolagas SC, Haussler MR, Deftos LJ 1980 1,25-Dihydroxyvitmn D3 receptor-like macromolecule in rat osteogenic sarcoma cell lines. J Biol Chem 225:44144417.
  • 20
    Narbaitz R, Stump WE, Sar M, DeLuca HF 1983 Autoradiographic localization of target cells for 1,25-Dihydroxyvitmn D3 in bones from fetal rats. Calcif Tissue Int 35:177182.
  • 21
    Erben RG, Brown S, Stangassinger M 1998 Therapeutic efficacy of 1α,25-dihydroxyvitamin D3 and calcium in osteopenic ovariectomized rats: Evidence for a direct anabolic effect of 1α,25-dihydroxyvitamin D3 on bone. Endocrinology 139:43194328.
  • 22
    Erben RG, Bante U, Birner H, Stangassinger M 1997 Prophylactic effects of 1,24,25-trihydroxyvitamin D3 on ovariectomy-induced cancellous bone loss in the rat. Calcif Tissue Int 60:434440.
  • 23
    Faugere M-C, Okamoto S, DeLuca HF, Malluche HH 1986 Calcitriol corrects bone loss induced by oophorectomy in rats. Clin Endocrinol Metab 13:E35E38.
  • 24
    Shiraishi A, Takeda A, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E 2000 Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. J Bone Miner Res 15:770779.
  • 25
    Shiraishi A, Higashi S, Masaki T, Ito M, Ikeda S, Nakamura T 2002 A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int 71:6979.
  • 26
    Nishikawa T, Ogawa S, Kogita K, Manabe N, Katsumata T, Nakamura K, Kawaguchi H 2000 Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats. Bone 27:647664.
  • 27
    Li M, Li Y, Healy DR, Simmons HA, Ke HZ, Thompson DD 2003 Alfacalcidol restores cancellous bone in ovariectomized rats. J Musculoskel Neuron Interact 3:3946.
  • 28
    Li M, Healy DR, Li Y, Simmons HA, Su M, Jee WSS, Shen VW, Thompson DD 2004 Alfacalcidol prevents age-related bone loss and causes an atypical pattern of bone formation in aged male rats. J Musculoskel Neuron Interact 4:2232.
  • 29
    Boehm MF, Fitzgerald P, Zou A, Elgort MG, Bischoff ED, Mere L, Mais DE, Bissonnette RP, Heyman R, Nadzan AM, Reichman M, Allegretto EA 1999 Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem Biol 6:265275.
  • 30
    Peleg A, Uskokovic M, Ahene A, Vickery B, Avnur Z 2002 Cellular and molecular events associated with the bone-protecting activity of noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology 143:16251636.
  • 31
    Peleg A, Ismail A, Uskokovic MR, Avnur Z 2003 Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem 88:267273.
  • 32
    Uchiyama Y, Higuchi Y, Takeda S, Masaki T, Shira-Ishi A, Sato K, Kubodera N, Ikeda K, Ogata E 2002 ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30:582588.
  • 33
    Kubodera N, Tsuji N, Uchiyama Y, Endo K 2003 A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients. J Cell Biochem 88:286289.
  • 34
    Matsumoto T, Shiraki M, Nakamura T, Hashimoto T, Itakura H, Suzuki K, Miki T, Hamada N, Sugimoto T, Kuroki Y, Fuji Y, Hagino H, Takata S, Ikeda S, Nakano T, Okamoto S, Hirota T, Tanigawara Y, Fukunaga M, Hayashi Y 2004 A new active vitamin D analog, ED-71, increases bone mass in osteoporotic patients under vitamin D supply: A randomized, double blind, placebo-controlled clinical study. Bone 34:S42.
  • 35
    Sicinski RR, Prahl JM, Smith CM, DeLuca HF 1998 New 1α, 25-dihydroxy-19-norvitamin D3 compounds of high biological activity: Synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem 41:46624674.
  • 36
    Yamamoto H, Shevde NK, Warrier A, Plum LA, DeLuca HF, Pike JW 2003 2-methylene-19-nor-(20S)-1,25-dihdroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem 278:3175631765.
  • 37
    Vanhooke JL, Benning MM, Bauer CB, Pike JW, DeLuca HF 2004 Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry 43:41014110.
  • 38
    Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pik JW, DeLuca HF 2002 A potent analog of 1α,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci USA 99:1348713491.
  • 39
    Ke HZ, Qi H, Chidsey-Frink KL, Crawford DT, Thompson DD 2001 Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res 16:765773.
  • 40
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595610.
  • 41
    Jee WSS, Li XJ, Inoue J, Jee KW, Haba T, Ke HZ, Setterberg RB, Ma YF 1997 Histomorphometric assay of the growing long bone. In: TakahashiH (ed.) Handbook of Bone Morphology. Nishimusa, Niigata City, Japan, pp. 87112.
  • 42
    Ke HZ, Shen V, Qi H, Crawford DT, Wu DD, Liang XG, Chidsey-Frink KL, Pirie CM, Simmons HA, Thompson DD 1998 Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia. Bone 23:249255.
  • 43
    Frost HM, Jee WS 1992 On the rat model of human osteopenias and osteoporoses. Bone Miner 18:227236.
  • 44
    Kalu DN 1991 The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175191.
  • 45
    Baumann BD, Wronski TJ 1995 Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 16:247253.
  • 46
    Kerner SA, Scott RA, Pike JW 1989 Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. Proc Natl Acad Sci USA 86:44554459.
  • 47
    Demay MB, Gerardi JM, DeLuca HF, Kronenberg HM 1990 DNA sequences in the rat osteocalcin gene that bind the 1,25-dihydroxyvitamin D3 receptor and confer responsive to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 87:369373.
  • 48
    Noda M, Vogel RL, Craig AM, Prahl J, DeLuca HF, Denhardt DT 1990 Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proc Natl Acad Sci USA 87:99959999.
  • 49
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:10511056.